Biomerieux, Inc.

Hospices Civils De Lyon

Hospices Civils De Lyon (hcl)

Centre National De La Recherche Scientifique

Universite Claude Bernard – Lyon1

Université Claude Bernard Lyon I

Centre Hospitalier Universitaire De Nantes

Université Claude Bernard

Guillaume Monneret

Alain Lepape

Fabienne Venet

Alexandre Pachot

Julien Textoris

Elisabeth Cerrato

Fanny Davin

Marie-Angelique Cazalis

Florence Frager

Benjamin Delwarde

Astrid Villars

Estelle Peronnet

Bruno Mougin

Tanguy Fortin

Karim Asehnoune

Charles Dumontet

Ahcene Boumendjel

Marilyne Dupin

Sylvie Pons

Maud Tournoud

Antoine Roquilly

Astrid Villars-Mechin

Bernard Allaouchiche

Aurélie Gouel-Cheron

Audrey Larue-Triolet

Marie-Angélique Cazalis

Sylvie Tissot

Julie Demaret

A kit for in vitro measurement of a at least one IL7R gene transcript in a blood sample, including specific reagents for measuring the transcript, and a control sample calibrated to contain the IL7R gene transcript corresponding to the mean quantity measured in a pool of reference blood samples from human patients in a state of septic shock when reference blood samples are taken, or who were in a state of septic shock within 72 h after taking the reference blood samples, and who were known to have survived, and/or a calibrated to contain the quantity of an IL7R gene transcript corresponding to the mean quantity measured in reference blood samples from patients in a state of septic shock when the reference blood samples are taken, or who were in a state of septic shock within 72 h after taking the reference blood samples, and not to have survived.

Kit for assessing the risk of complications in patients with systemic inflammatory response syndrome (SIRS)

Disclosed herein is a method for the diagnosis/prognosis of a septic syndrome based on a biological sample from a patient. The method may include extracting biological material the biological sample, contacting the biological material with at least one specific reagent that is selected from specific reagents for the target genes having a nucleic acid sequence of any one of SEQ ID NOs: 1 to 28, and determining the expression of at least one of the target genes.

Method for diagnosis and/or prognosis of a septic syndrome

The subject of the invention is a method for making an in vitro prognosis of severity for a patient in septic shock, including the following steps: (i) the level of expression of the expression product of at least one gene chosen from the lilrb2 and lilrb1 genes is measured in vitro on the basis of a biological sample taken from the patient, (ii) the level of expression of the expression product of the at least one gene is compared with a control level of expression, of the expression product of the same gene, with a good prognosis of severity, in which a level of expression of the expression product of the at least one gene below the control level of expression indicates a poor prognosis of severity for the patient, and also a kit for implementing the method.

Method and kit for making an in vitro prognosis of severity for a patient in septic shock

The invention concerns a method of in vitro or ex vivo evaluation of the risk of complications in a patient who has sustained an insult or an infection generating a systemic inflammatory response syndrome, the method being characterized in that it comprises the step of detecting, in a biological sample obtained from said patient, at least one transcript of the IL7R gene, as well as measuring, in vitro or ex vivo, the quantity of at least one transcript of the IL7R gene, in a biological sample from a patient who has sustained an insult or an infection generating a systemic inflammatory response syndrome, in order to evaluate the risk of complications, and in particular of mortality, in said patient. The invention also concerns kits for measuring, in vitro or ex vivo, the quantity of at least one transcript of the IL7R gene in a biological sample.

Method for assessing the risk of complications in patients with systemic inflammatory response syndrome (sirs)

A method for determining a patient's susceptibility of contracting a nosocomial infection that includes obtaining a biological sample from the patient and extracting biological material from the biological sample; preparing a specific reagent of an expression product of at least one target gene selected from S100A9 and S100A8 target genes; and determining the expression of at least one of the target genes S100A9 and S100A8, where overexpression relative to a specified threshold value indicates susceptibility of contracting a nosocomial infection.

Methods for determining a patient's susceptibility of contracting a nosocomial infection and for establishing a prognosis of the progression of septic syndrome

The present invention relates to a process for determining in vitro the immune status of an individual according to which: (a) a blood sample from the individual is provided, (b) at least two reagents specific to at least two products of expression of at least two target genes are provided; (c) the expression of said at least two target genes is determined, and (d) the expression of said at least two target genes respectively is compared with a reference expression, with a change in the expression of said at least two target genes relative to their reference expression indicating that the individual's immune status has changed, and a correlation between the expression of said at least two target genes with their reference expression indicating that the individual's immune status is normal; as well as a kit for determining said immune status of the individual.

Process and kit for determining in vitro the immune status of an individual

The present invention relates to a method for the diagnosis/prognosis of a septic syndrome based on a biological sample from a patient, characterized in that it comprises the following steps:

A kit for in vitro or ex vivo measurement of sCD127 expression in a biological sample, the kit including:

Kit for in vitro or ex vivo measurement of SCD127 expression in a biological sample

The invention provides a method of evaluating the risk of mortality in patients who present a systemic inflammatory response (SIRS) or septic syndromes, comprising measuring the expression of sCD127 in a biological sample.

Method for evaluating the risk of mortality in patients who exhibit a systemic inflammatory response syndrome (SIRS) or sepsis

A method for predicting the risk of developing a disseminated infection in a patient admitted to intensive care having no clinical symptoms of such infection includes: determining a first dose of gelsolin G1 in a biological sample from the patient originating from a first sample taken at time T1, carried out between the day of intensive care admission and 48 hours afterward; determining a second dose of gelsolin G2 in a biological sample from the patient originating from a second sample taken at time T2, carried out two to three days after the first sampling; calculating the variation between the dose of gelsolin G2 and the dose of gelsolin G1, giving a &#x394; value; and comparing the &#x394; value to a threshold value S determined beforehand from two patient populations admitted to intensive care, one not having developed a disseminated infection and the other having developed such an infection.

Prediction of the risk of developing a disseminated infection for patients admitted to an intensive care unit

The present invention relates to the compounds of formula (I): wherein:

Chalcone derivatives having an anti-allergic activity

The invention relates to a process for determining the susceptibility to nosocomical infections in a patient, comprising the measurement of the expression of sCD127 in a biological sample.

Process for determining the susceptibility to nosocomial infections

A method and a kit for establishing an in vitro prognosis on a patient exhibiting SIRS, the method comprising: (i) measuring the level of expression of the CX3CR1 gene in vitro from the biological material of a patient sample by bringing into contact said sample with a specific reagent of the CX3CR1 gene; and (ii) comparing the expression level of the CX3CR1 gene of the patient to a predetermined expression threshold; wherein (iii) if the expression level of the CX3CR1 gene of the patient is less than the predetermined expression threshold, the survival prognosis of the patient is poor, and if the expression level of the CX3CR1 gene of the patient is greater than the predetermined expression threshold, the survival prognosis of the patient is good.

Growing community of inventors

Lyons, France

Guillaume Monneret